
HHS announces efforts to eliminate independent conclusion of GRAS
U.S. Department of Health and Human Services (HHS) Secretary, Robert F. Kennedy Jr., is directing the acting U.S. Food and Drug Administration’s (FDA) acting commissioner to explore rulemaking that would eliminate the independent conclusion of GRAS provision.
In a
“For far too long, ingredient manufacturers and sponsors have exploited a loophole that has allowed new ingredients and chemicals, often with unknown safety data, to be introduced into the U.S. food supply without notification to the FDA or the public,” said Kennedy, in the press release. “Eliminating this loophole will provide transparency to consumers, help get our nation’s food supply back on track by ensuring that ingredients being introduced into foods are safe, and ultimately Make America Healthy Again.”
While independent conclusions of GRAS do not require notification to FDA, companies making the determination still have to assemble an independent panel to review existing safety data such as toxicological studies and create a dossier of the data demonstrating the ingredient’s safety. Additionally, all data establishing the safety of the ingredient must be
While independent conclusions of GRAS must use publicly available safety data, there is no database of these conclusions. Some third parties, such as
The release offered no timeline for eliminating the independent conclusion provision, but did state that HSS is also committed to seeking legislative means to change the process.
“The FDA is committed to further safeguarding the food supply by ensuring the appropriate review of ingredients and substances that come into contact with food,” said acting FDA commissioner Sara Brenner, MD., MPH. “The FDA will continue to follow our authorities and leverage our resources to protect the health of consumers to ensure that food is a vehicle for wellness.”
The Council for Responsible Nutrition's (CRN; Washington, D.C.) senior vice president of scientific and regulatory affairs was critical of the new effort. In a statement, Wong said, "Rather than dismantling a system that allows scientifically reviewed ingredients to reach the market efficiently, FDA should focus on strengthening enforcement mechanisms to ensure the GRAS process is used responsibly. CRN shares the goal of increasing safety and transparency for consumers and stands ready to work with the FDA to achieve it. The solution is not to eliminate self-GRAS, which would stifle innovation, but to provide FDA with the resources and tools it needs to maintain an effective regulatory system that fosters both safety and progress."
Newsletter
From ingredient science to consumer trends, get the intel you need to stay competitive in the nutrition space—subscribe now to Nutritional Outlook.





